Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow KNSA by emailGet an email when KNSA pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about KNSA, unsubscribe in one click. Privacy
📣 What KNSA Says Is Next
by the end of 2026 · “The company expects to initiate a Phase 1 first-in-human clinical trial by the end of 2026. * Reported as median (95% confidence interval). 1 Treatment Response is defined as Pain Response (NRS score ≤ 2 on the 11-point daily pericarditis pain NRS pain scale) and at least one CRP level ≤ 0.5 mg/dL within 7 days before or after the Pain Response. 2 CRP Normalization is defined as CRP ≤ 0.5 mg/dL. 2 Financial Results”
Company press release, Jul 28, 2026 · SEC filing
this year · “Additionally, we continue to develop KPL-1161 with a target profile of once-quarterly dosing and are on track to initiate a Phase 1 trial by the end of this year.” Portfolio Execution ARCALYST (IL-1α and IL-1β cytokine trap)”
Company press release, Jul 28, 2026 · SEC filing
by the end of 2026 · “The company expects to initiate a Phase 1 first-in-human clinical trial by the end of 2026.”
Company press release, Apr 28, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full KNSA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KNSA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.